Körner, Maria
Müller, Paul https://orcid.org/0009-0003-4673-4333
Das, Hirak https://orcid.org/0009-0009-6060-1557
Kraus, Felix
Pfeuffer, Timo https://orcid.org/0009-0000-2365-9113
Spielhaupter, Sven https://orcid.org/0009-0005-7386-4576
Oeljeklaus, Silke https://orcid.org/0000-0001-8908-4295
Schülein-Völk, Christina
Harper, J. Wade https://orcid.org/0000-0002-6944-7236
Warscheid, Bettina https://orcid.org/0000-0001-5096-1975
Buchberger, Alexander https://orcid.org/0000-0002-2836-0820
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GRK2243/1+2, BU951/5-1, INST 93/1023-1-FUGG, GRK2243/2, FOR2743)
EC | Horizon 2020 Framework Programme (Marie Skłodowska-Curie grant agreement No 812968, Marie Skłodowska-Curie grant agreement No 812968)
Goldberg Fellowship of the Cell Biology Education and Fellowship Fund at Harvard Medical School
Article History
Received: 12 July 2024
Accepted: 23 April 2025
First Online: 7 May 2025
Competing interests
: J.W.H. is a consultant and founder of Caraway Therapeutics (a wholly owned subsidiary of Merck & Co., Inc.) and is a member of the scientific advisory board for Lyterian Therapeutics. The remaining authors declare no competing interests.